A new study in the journal Human Gene Therapy showed that more than half of individuals with Niemann-Pick disease, type C1 (NPC1) who were tested lacked neutralizing antibodies against either adeno-associated virus (AAV) 2 or AAV9.
The virus that causes COVID-19 has been very good at mutating to keep infecting people—so good that most antibody treatments developed during the pandemic are no longer effective. Now a team led by Stanford University researchers may have found a way t…
Your immune system harbors a lifetime’s worth of information about threats it’s encountered—a biological Rolodex of baddies. Often the perpetrators are viruses and bacteria you’ve conquered; others are undercover agents like vaccines given to trigger p…
Scientists have a new target to prevent cold sores after University of Virginia School of Medicine researchers discovered an unexpected way the herpes virus re-activates in the body. The finding could also have important implications for genital herpes…
Brazilian researchers have developed a simple test that almost instantly tells whether a person has been exposed to any of the four dengue virus serotypes, as well as Zika virus. The test is an enzyme immunoassay similar to ELISA, a platform widely use…
A team of Yale School of Medicine infectious diseases researchers recently conducted an in-depth review of the literature on how one genus of viruses, known as flaviviruses, manipulates mitochondria to evade immune responses. Annually, more than 3 bill…
A bone marrow transplant process co-developed by investigators at the Johns Hopkins Kimmel Cancer Center is safe and curative for adults with sickle cell disease, according to results of a trial completed at Johns Hopkins and about 20 additional cancer…
Scientists at La Trobe University have identified a possible defense for humans against the influenza virus H5N1—commonly known as “bird flu”—which could open avenues of research for new vaccine development.
Children who experience multiple cases of dengue virus develop an army of dengue-fighting T cells, according to a new study led by scientists at La Jolla Institute for Immunology (LJI).
New research led by scientists at La Jolla Institute for Immunology (LJI) reveals the workings of a human antibody called mAb 3A6, which may prove to be an important component for Ebola virus therapeutics.
